Abbott India September profit rises 9% to Rs 453 crore

Abbott India Limited reported profit of Rs 453.45 crore for the quarter ended September 30, 2026, 9% higher than Rs 415.27 crore a year earlier, as revenue from operations increased 11% to Rs 1,951.01 crore. Profit before tax rose to Rs 610.47 crore from Rs 545.93 crore in the comparable quarter.

What did Abbott India report for the September 2026 quarter?

Abbott India reported total income of Rs 2,019.07 crore for the quarter ended September 30, 2026, compared with Rs 1,827.10 crore for the quarter ended September 30, 2025. Revenue from operations was Rs 1,951.01 crore, while other income was Rs 68.05 crore. The Board approved the unaudited results on November 5, 2026.

Profit for the September 2026 quarter was Rs 453.45 crore, compared with Rs 415.27 crore in the year-earlier quarter and Rs 428.52 crore in the quarter ended June 30, 2026. Basic and diluted earnings per equity share were Rs 213.39, against Rs 195.42 a year earlier. Abbott India disclosed pharmaceuticals as its only operating segment.

How did Abbott India’s revenue and profit compare across periods?

Abbott India’s revenue from operations increased by Rs 193.86 crore year on year, from Rs 1,757.15 crore in the September 2025 quarter to Rs 1,951.01 crore in the September 2026 quarter. Profit increased by Rs 38.18 crore over the same comparison, from Rs 415.27 crore to Rs 453.45 crore. Other income declined by Rs 1.90 crore to Rs 68.05 crore.

On a sequential basis, September-quarter revenue rose by Rs 137.33 crore from Rs 1,813.68 crore in the June 2026 quarter. Quarterly profit rose by Rs 24.93 crore from Rs 428.52 crore, while profit before tax increased by Rs 38.26 crore from Rs 572.21 crore. Total income increased from Rs 1,889.05 crore in June 2026 to Rs 2,019.07 crore in September 2026.

For the six months ended September 30, 2026, Abbott India recorded revenue from operations of Rs 3,764.69 crore, compared with Rs 3,495.50 crore in the corresponding six months of 2025. Six-month profit rose to Rs 881.97 crore from Rs 781.13 crore, while profit before tax increased to Rs 1,182.68 crore from Rs 1,039.06 crore. The filing provides no product-level or geographic revenue split within the pharmaceuticals segment.

What changed in Abbott India’s costs and tax during the quarter?

Abbott India’s total expenses were Rs 1,408.60 crore in the September 2026 quarter, compared with Rs 1,281.17 crore in the September 2025 quarter. Cost of materials consumed was Rs 835.62 crore, employee benefits expense was Rs 180.40 crore and other expenses were Rs 192.85 crore. Finance costs were Rs 5.95 crore and depreciation and amortisation expense was Rs 19.49 crore.

The increase in quarterly total expenses was Rs 127.43 crore, less than the Rs 191.97 crore increase in total income between the September 2025 and September 2026 quarters. Tax expense rose to Rs 157.02 crore from Rs 130.66 crore, following the increase in profit before tax to Rs 610.47 crore from Rs 545.93 crore. The resulting reported profit was Rs 453.45 crore.

For the six months ended September 30, 2026, total expenses were Rs 2,725.44 crore, compared with Rs 2,599.23 crore in the prior-year six-month period. Tax expense was Rs 300.71 crore, against Rs 257.93 crore a year earlier. Revenue from operations increased by Rs 269.19 crore over the same six-month comparison, while expenses increased by Rs 126.21 crore.

What do Abbott India’s balance sheet and cash flows show?

Abbott India had total assets of Rs 5,924.91 crore as of September 30, 2026, compared with Rs 6,501.93 crore as of March 31, 2026. Total equity was Rs 4,270.20 crore, down from Rs 4,774.19 crore, while equity share capital remained Rs 21.25 crore. Other equity was Rs 4,248.95 crore at September 30, 2026.

Current assets increased to Rs 3,921.08 crore at September 30, 2026 from Rs 3,770.69 crore at March 31, 2026. Cash and cash equivalents rose to Rs 837.44 crore from Rs 442.33 crore, and trade receivables increased to Rs 471.31 crore from Rs 361.73 crore. Inventories were Rs 962.77 crore, compared with Rs 947.26 crore at the March 2026 year-end.

Net cash generated from operating activities was Rs 658.97 crore for the six months ended September 30, 2026, compared with Rs 521.94 crore in the corresponding 2025 period. Investing activities generated Rs 1,159.19 crore, while financing activities used Rs 1,423.05 crore, including dividend payments of Rs 1,393.95 crore. Cash and cash equivalents at the end of the period were Rs 837.44 crore, compared with Rs 591.10 crore a year earlier.

Conclusion

Abbott India’s September 2026 filing shows higher revenue and profit than both the September 2025 and June 2026 quarters. Revenue from operations reached Rs 1,951.01 crore, quarterly profit was Rs 453.45 crore and six-month profit was Rs 881.97 crore. The reported improvement occurred within the company’s single disclosed pharmaceuticals segment.

The main unresolved detail is the absence of product-line and geographic disclosures within the pharmaceuticals segment for the six months ended September 30, 2026. Future results can show whether revenue, which rose by Rs 269.19 crore year on year in the six-month period, continues to outpace changes in expenses and whether trade receivables, at Rs 471.31 crore, change further.